MSTN and proximal spinal muscular atrophy: Although clinical trials investigating new classes of SMA treatments (e.g., apitegromab, a selective myostatin inhibitor) are currently underway,17 present experience with these new treatments in real‐world practice is insufficient to inform rationale for integration into a classification schema such as this.